3 / 5 Stars
5 4 2 4 4
Zacks Investment Research
5 (Strong Sell)
Standard & Poor's
5 / 5 Stars
#13 in Health
U.S. News evaluated 33 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.
The fund has returned 40.04 percent over the past year, 35.08 percent over the past three years, 27.89 percent over the past five years, and 13.29 percent over the past decade.
|Trailing Returns||Updated 06.30.2014|
|Year to date||9.7%|
|3 Years (Annualized)||35.1%|
|5 Years (Annualized)||27.9%|
|10 Years (Annualized)||13.3%|
The investment seeks capital appreciation. The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions, to select investments. The fund is non-diversified.
Fees are Low compared to funds in the same category.
Fidelity Advisor® Biotechnology Fund has an expense ratio of 1.14 percent.
Risk is Above Average compared to funds in the same category according to Morningstar.